Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Ephedra is back

This article was originally published in The Tan Sheet

Executive Summary

American Generics Laboratories has launched four new ephedra-containing weight-loss supplements "as a result of high consumer demand following the recent overturning of the 2004 FDA ban on ephedra-based products," according to an announcement Nov. 16. The Salt Lake City, Utah-based firm was founded in August and is marketing Superdrine RX-10, Ripped Power, Metabothin and Super Ephedra Extreme online for $39.99 - $59.99. "The products are manufactured in FDA-approved facilities and are of daily dosages permitted by law," the firm maintains. FDA banned dietary supplements containing ephedrine alkaloids in 2004. However, a Utah District Court overturned the ban in April for Nutraceutical Corporation's 10 mg product. FDA is appealing the court's decision (1"The Tan Sheet" Nov. 14, 2005, p. 4)...

Topics

Latest Headlines
See All
UsernamePublicRestriction

Register

PS098868

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel